#3 - AbbVie (NYSE:ABBV)
If you’re looking for a company that’s delivering market-beating performance without the controversy surrounding vaccine plays, AbbVie (NYSE:ABBV) is an exceptional choice. In addition to having several established drugs, like Humira, the company has a robust pipeline that gives investors reason to believe the company will continue to deliver strong revenue and earnings even when Humira faces generic competition in the United States.
Another reason to look at AbbVie is as a hedge against inflation. The company offers an exceptionally reliable dividend as evidenced by its inclusion in the elite Dividend Aristocrat club. This means it has increased its dividend for at least the last 25 years. In the case of AbbVie, the number is 49 years which puts it one year away from being a Dividend King.
That being said, ABBV stock is at or near an all-time high. And some investors may wonder how much upside is left. The analysts tracked by MarketBeat do give the stock a slightly higher price. The stock looks to be trying to find support just below its all-time high. If it’s successful, investors may be looking at another leg higher.
About AbbVie
AbbVie Inc discovers, develops, manufactures, and sells pharmaceuticals worldwide. The company offers Humira, an injection for autoimmune and intestinal Behçet's diseases, and pyoderma gangrenosum; Skyrizi to treat moderate to severe plaque psoriasis, psoriatic disease, and Crohn's disease; Rinvoq to treat rheumatoid and psoriatic arthritis, ankylosing spondylitis, atopic dermatitis, axial spondyloarthropathy, ulcerative colitis, and Crohn's disease; Imbruvica for the treatment of adult patients with blood cancers; Epkinly to treat lymphoma; Elahere to treat cancer; and Venclexta/Venclyxto to treat blood cancers.
Read More - Current Price
- $175.58
- Consensus Rating
- Moderate Buy
- Ratings Breakdown
- 19 Buy Ratings, 5 Hold Ratings, 0 Sell Ratings.
- Consensus Price Target
- $205.70 (17.2% Upside)
